Navigation Links
Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
Date:8/7/2008

million for the second quarter of 2008 and $22 million for the first six months of 2008, as compared to $12 million and $22 million recorded in the prior year periods, respectively.

Margins

Generic: Margins in the generic segment for the second quarter of 2008 and the first six months of 2008 were 45% and 47%, respectively, compared to 49% and 47%, respectively, in the prior year periods.

Proprietary: Margins in the proprietary segment for both the second quarter of 2008 and the first six months of 2008 were 69%, down from 78% and 72% in the prior year periods, respectively, principally due to higher product amortization.

Update on R&D Activities

Research and development expenses totaled $81 million for the second quarter of 2008, compared to $66 million in the prior year period. R&D for the first six months of 2008 totaled $145 million, compared to $129 million for the prior year period. The increases reflect greater investment in generic and bio-generic development activities, both in the U.S. and Europe, as well as in proprietary development activities in the United States and the impact of foreign currency exchange.

Generic Products

At June 30, 2008, the Company had approximately 70 Abbreviated New Drug Applications, including tentatively approved applications, pending at the U.S. Food and Drug Administration (FDA) targeting branded pharmaceutical products with an estimated $29 billion in sales. The Company also had approximately 350 product registrations, representing 89 molecules, pending with regulatory bodies in Europe and ROW.

During the second quarter of 2008, the Company received two generic product approvals in the U.S. from the FDA, and approximately 20 approvals, representing 13 molecules, from regulatory bodies in Europe and ROW.

Proprietary Products

The Company currently has an extensive proprietary clinical development program that includes four products in Phase III studies and
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
2. Caliper Life Sciences Reports Second Quarter 2008 Results
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. EntreMed Reports Second Quarter 2008 Financial Results
5. Transgenomic Reports Second Quarter 2008 Results
6. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
7. Bionovo Reports Second Quarter 2008 Financial Results
8. AtriCure Reports Record Second Quarter 2008 Financial Results
9. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
10. eResearchTechnology Reports Second Quarter 2008 Results
11. SuperGen Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Report Details Biosimilar ... potential revenues Do you want to find sales ... revenue predictions for those biological drugs from 2014, ... find financial data, R&D trends, opportunities and selling ... forecasts to 2024 at overall world market, therapeutic ...
(Date:9/30/2014)... Over the last decade, the laboratory filtration market ... and increased acceptance of new filtration technologies in end ... are also catalyzing the growth of laboratory filtration market. ... grow at a strong CAGR during the forecast period ... million by 2019. The market is mainly driven by ...
(Date:9/30/2014)... Md. , Sept. 30, 2014  RegeneRx ... today announced that it has received a Canadian ... by Actin-Sequestering Peptides.  This patent includes claims using ... numerous other actin-sequestering peptides for these purposes.  The ... About RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... Genedata, a leading provider ... and related life science research, today announced ... Selector as its host-pathogen data analysis platform ... a European consortium dedicated to improving the ... anti-fungal drug therapies. Genedata Selector supports this ...
Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3
... Inovail, successfully launches ... OmegaGen(R) in Australia and New Zealand, LAVAL, QC, ... (NASDAQ.NEPT - TSX.V.NTB) and its commercial,pharmaceutical partner Inovail Pty ... complementary medicine in Australia and New,Zealand. Neptune foresees this ...
... BASINGSTOKE, England, March 25 Shire plc,(LSE: SHP, ... preliminary results prepared under International Financial,Reporting Standards ("IFRS") ... On February 21, 2008 Shire announced its ... Notes to Editors, Shire plc, Shire,s ...
... IRVINE, Calif., March 25 Masimo (Nasdaq:,MASI), ... Motion and Low,Perfusion pulse oximetry, today announced ... manufacturer and supplier of,electrocardiographs, spirometers, patient monitors ... SET technology platform as,the foundational technology of ...
Cached Biology Technology:Neptune Technologies expands into medicinal markets in Asia Pacific 2Neptune Technologies expands into medicinal markets in Asia Pacific 3Shire plc: IFRS Results for the Year Ending December 31, 2007 2Shire plc: IFRS Results for the Year Ending December 31, 2007 3Shire plc: IFRS Results for the Year Ending December 31, 2007 4Shire plc: IFRS Results for the Year Ending December 31, 2007 5Shire plc: IFRS Results for the Year Ending December 31, 2007 6Shire plc: IFRS Results for the Year Ending December 31, 2007 7Shire plc: IFRS Results for the Year Ending December 31, 2007 8Shire plc: IFRS Results for the Year Ending December 31, 2007 9Shire plc: IFRS Results for the Year Ending December 31, 2007 10Shire plc: IFRS Results for the Year Ending December 31, 2007 11Shire plc: IFRS Results for the Year Ending December 31, 2007 12Shire plc: IFRS Results for the Year Ending December 31, 2007 13Shire plc: IFRS Results for the Year Ending December 31, 2007 14Shire plc: IFRS Results for the Year Ending December 31, 2007 15Shire plc: IFRS Results for the Year Ending December 31, 2007 16Shire plc: IFRS Results for the Year Ending December 31, 2007 17Shire plc: IFRS Results for the Year Ending December 31, 2007 18Shire plc: IFRS Results for the Year Ending December 31, 2007 19Shire plc: IFRS Results for the Year Ending December 31, 2007 20Shire plc: IFRS Results for the Year Ending December 31, 2007 21Shire plc: IFRS Results for the Year Ending December 31, 2007 22Shire plc: IFRS Results for the Year Ending December 31, 2007 23Shire plc: IFRS Results for the Year Ending December 31, 2007 24Shire plc: IFRS Results for the Year Ending December 31, 2007 25Shire plc: IFRS Results for the Year Ending December 31, 2007 26Shire plc: IFRS Results for the Year Ending December 31, 2007 27Shire plc: IFRS Results for the Year Ending December 31, 2007 28Shire plc: IFRS Results for the Year Ending December 31, 2007 29Shire plc: IFRS Results for the Year Ending December 31, 2007 30Shire plc: IFRS Results for the Year Ending December 31, 2007 31Shire plc: IFRS Results for the Year Ending December 31, 2007 32Shire plc: IFRS Results for the Year Ending December 31, 2007 33Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide 2
(Date:9/30/2014)... what goes wrong with your muscles because of age, disease ... actually is. That,s where a new research report published in ... comes in. In the report, a team of ... can help scientists "see" which genes are active in an ... gene activity and that men have approximately 400 more active ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014 /PRNewswire/ ... control solutions for the biotech and power ... its new RECONN Bioprocess Manager, an easy-to-use ... solution geared towards bioprocess development laboratories. ... have disparate bioreactor and analyzer systems. Accessing ...
(Date:9/30/2014)... 30, 2014 Winners of The Economist,s prestigious ... scheduled to take place at the JW Marriott Hong Kong on ... winners will share their experiences and the lessons those hold for ... proven innovation over the past decade, will be presented at a ... the summit. It will be the first time the ceremony has ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Spectra Automation Introduces RECONN Bioprocess Manager 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... WASHINGTON, N.C. , Oct. 21, 2013 Washington Eye Center ... Eye Care, effective immediately. The name was chosen to better reflect ... come to expect from Eastern North Carolina,s ... Eye Care will be the new name of the locations in ...
... map shows that most tropical rain falls in the Northern ... inches of rain a year, while an equal distance on ... long believed that this was a quirk of the Earth,s ... planet spins pushed tropical rain bands north of the equator. ...
... researchers used suction to learn that individual "molecular muscles" within ... may explain how cells "feel" the environment and appropriately adapt ... published online Oct. 20 in the journal Nature Materials ... are translated into internal signals. A computer model ...
Cached Biology News:Washington Eye Center is now Precision Eye Care 2Global ocean currents explain why Northern Hemisphere is the soggier one 2Cells' 'molecular muscles' help them sense and respond to their environments 2Cells' 'molecular muscles' help them sense and respond to their environments 3
... temperature control for microbiology and cell culture. ... is suitable for DASGIP bioreactors from 150 ... temperature ranges from approximately 10 °C to ... with an individual electrical heating element with ...
... gel stain is a sensitive nucleic acid ... to RNA and low background in gels, making ... polyacrylamide gels using laser scanners or standard UV ... mL unit size (S-7568) and a special packaging ...
... reports the data from any one of IITC ... recorder. The final data is sent from the ... is automatic for Systolic, Mean, Heart Rate while ... is always in the position to override the ...
Sirtuin 7 (SIRT7) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: Other Recommended Storage: Long term: -20C; Short term: +4C...
Biology Products: